WuXi XDC Cayman gets GMP release for Singapore Tuas site
WuXi XDC Cayman Inc. said it received GMP release for its Singapore manufacturing site at Tuas Biomedical Park, including the BCM3 dual-function line and the DP4 facility, enabling global dual-sourcing for bioconjugate manufacturing.
WuXi XDC Cayman Inc. said its Singapore site at Tuas Biomedical Park has received GMP release, covering the BCM3 dual-function line and the DP4 facility. The company said the release enables global dual-sourcing for bioconjugate manufacturing.